Engineered immune cells are demonstrating remarkable staying power in laboratory tests against aggressive cancers like pancreatic and gastric cancer, offering a potential new avenue for treatment where options are often limited. Researchers are focusing on a specific type of immune cell, the invariant natural killer T cell (iNKT cell), and equipping it with the ability to precisely target cancer cells while minimizing harm to healthy tissue. This approach, detailed in recent preclinical data from Arovella Therapeutics (ASX:ALA), centers on a modified iNKT cell engineered to express a chimeric antigen receptor (CAR) targeting a protein called claudin 18.2.
The promise of CAR-T cell therapy – engineering a patient’s own immune cells to fight cancer – has largely been realized in blood cancers like leukemia and lymphoma. However, solid tumors, like those found in the pancreas and stomach, have proven far more challenging. These tumors create a complex environment that suppresses immune cell activity, and getting engineered cells to effectively infiltrate and persist within the tumor remains a significant hurdle. Arovella’s research suggests a way to overcome some of these obstacles, focusing on the protein claudin 18.2, which is frequently found on the surface of these cancer cells but largely hidden in healthy gastric tissue. The findings, initially reported by Biotech Dispatch, highlight the potential of this targeted approach.
Targeting Claudin 18.2: A Selective Strike
Claudin 18.2’s unique expression pattern makes it an attractive target for cancer therapy. In healthy gastric tissue, the protein resides within tight junctions between cells, effectively shielded from immune detection. However, as cancer develops, claudin 18.2 becomes more exposed on the cell surface, allowing engineered immune cells to recognize and attack the tumor with greater specificity. This is particularly important for cancers that lack other readily identifiable biomarkers, leaving clinicians with fewer treatment options. According to the National Cancer Institute, pancreatic cancer, in particular, is often diagnosed at a late stage, when treatment options are limited and the prognosis is poor. Learn more about pancreatic cancer.
‘Armoring’ the Immune Cells for Endurance
The Arovella Therapeutics research revealed that simply equipping the iNKT cells with the CAR targeting claudin 18.2 wasn’t enough to ensure long-lasting effectiveness. The engineered cells initially demonstrated strong cytotoxic activity – the ability to kill cancer cells – in laboratory experiments. However, their effectiveness waned when repeatedly challenged with reintroduced tumor cells, mimicking the ongoing pressure of a developing cancer. The key to improving persistence, researchers found, was “armoring” the CAR-iNKT cells with a molecule called IL-12-TM.
IL-12 is a cytokine, a signaling molecule that boosts immune cell function. The IL-12-TM modification enhances the engineered cells’ ability to expand and sustain their killing capacity over successive tumor challenges. Data from the preclinical studies showed that the armored CAR-iNKT cells eliminated more than 97% of pancreatic cancer cells and over 80% of gastric cancer cells, even after repeated exposures. This level of endurance suggests a significant therapeutic potential, as it indicates the cells can maintain a robust immune response over time.
Overcoming Challenges in Solid Tumor Therapy
Solid tumors present a unique set of challenges for cell therapy. Beyond the immunosuppressive environment, issues like poor cell persistence (the cells don’t stick around long enough to do their job) and limited infiltration (the cells can’t effectively reach the tumor) have hampered progress. Arovella’s platform appears to address both of these issues by combining targeted CAR design with cytokine “armoring.” This combination enhances both the potency – the strength of the immune response – and the durability – how long the response lasts – two critical parameters for clinical success.
Researchers emphasize that these results are currently preclinical, meaning they have been observed in laboratory settings and have not yet been tested in humans. The next step, according to Arovella Therapeutics leadership, is to move beyond in vitro systems and into animal models. These studies will assess the therapy’s performance in a more complex biological environment, providing valuable insights into its safety and efficacy before potential human trials. The company views these findings as a validation of both its targeting strategy and its armor technology.
What is CAR-T Cell Therapy?
CAR-T cell therapy, or Chimeric Antigen Receptor T-cell therapy, is a type of immunotherapy that uses genetically engineered T cells to fight cancer. T cells, a type of white blood cell, are extracted from the patient’s blood and modified in a lab to express a CAR. This CAR allows the T cells to recognize and bind to a specific protein (antigen) on cancer cells. The modified T cells are then infused back into the patient, where they can seek out and destroy cancer cells. The National Cancer Institute provides a comprehensive overview of CAR-T cell therapy.
The development of effective therapies for pancreatic and gastric cancer remains a critical area of research. These cancers are often diagnosed at late stages and have limited treatment options. The promising preclinical data from Arovella Therapeutics offers a glimmer of hope, suggesting that engineered immune cells, particularly when “armored” to enhance their persistence, could play a significant role in future treatment strategies. The upcoming animal studies will be crucial in determining whether these laboratory findings translate into a viable therapeutic option for patients.
Disclaimer: The information provided in this article is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts on this promising research in the comments below, and please share this article with anyone who might find it informative.
